Published in Ann Oncol on April 01, 2004
Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol (2011) 1.25
Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry (2006) 0.85
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol (2010) 2.03
Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology (2005) 1.89
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol (2004) 1.51
Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res (2008) 1.49
Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc (2000) 1.48
Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet (1989) 1.33
Mediastinoscopy as a standardised procedure for mediastinal lymph-node staging in non-small cell carcinoma. Do we have to accept the compromise? Eur J Cardiothorac Surg (2001) 1.22
Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol (2006) 1.19
Fundamental gating mechanism of nicotinic receptor channel revealed by mutation causing a congenital myasthenic syndrome. J Gen Physiol (2000) 1.18
Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer (2002) 1.16
Myasthenia gravis during interferon alfa therapy. Neurology (1995) 1.10
Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif (2008) 1.07
EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol (2014) 1.06
Thymoma in patients with MG: characteristics and long-term outcome. Neurology (2002) 1.06
SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol (2000) 1.06
Results of thoracoscopic pleural abrasion for primary spontaneous pneumothorax. Surg Endosc (2004) 1.02
Thymic lesions and myasthenia gravis. Diagnosis based on mediastinal imaging and pathological findings. Acta Radiol (2002) 0.99
Elastofibroma dorsi: clinicopathological analysis of 71 cases. Thorac Cardiovasc Surg (2013) 0.98
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer (2013) 0.96
Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci (1991) 0.96
Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96
Subpopulations of T lymphocytes in myasthenia gravis patients. Clin Exp Immunol (1979) 0.95
Surgical treatment of achalasia: a retrospective comparative study. Surg Today (1993) 0.95
Course and treatment of myasthenia gravis during pregnancy. Neurology (1999) 0.94
Conservative surgery for early cancer of the distal rectum. Dis Colon Rectum (1992) 0.94
Non-small cell lung cancer with single brain metastasis: the role of surgical treatment. Eur J Cardiothorac Surg (2001) 0.92
Intraoperative esophageal manometry in surgical treatment of achalasia: a reappraisal. Hepatogastroenterology (1997) 0.92
Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology (2005) 0.92
Prosthetic reconstruction of the chest wall. Int Surg (1994) 0.92
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology (2009) 0.92
Treatment of advanced non-small cell lung cancer. Ann Oncol (2006) 0.91
Myasthenia gravis, thymectomy, and antiacetycholine receptor antibody. J Neurol (1980) 0.91
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer (2011) 0.91
Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire. Neurol Sci (2002) 0.91
Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology (2006) 0.89
Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system. Curr Med Chem (2006) 0.89
Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells. Cell Mol Life Sci (2006) 0.88
Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment. Curr Med Chem (2011) 0.88
Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord (2001) 0.88
Pneumocephalus after Pancoast's tumor surgery: to be or not to be conservative? J Cardiovasc Surg (Torino) (2007) 0.88
Esophageal diverticula. Physiopathological basis for surgical management. Eur J Cardiothorac Surg (1992) 0.87
Multitarget drugs of plants origin acting on Alzheimer's disease. Curr Med Chem (2013) 0.87
Neonatal myasthenia gravis: clinical and immunological study of seven mothers and their newborn infants. J Neuroimmunol (1986) 0.87
Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy. Curr Med Chem (2012) 0.87
The difficulty in confirming clinical diagnosis of myasthenia gravis in a seronegative patient: a possible neurophysiological approach. Neuromuscul Disord (2009) 0.87
Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci (2001) 0.87
Role of combined 18F-FDG-PET/CT for predicting the WHO malignancy grade of thymic epithelial tumors: a multicenter analysis. Lung Cancer (2013) 0.86
Therapeutic apheresis in myasthenia gravis. Ther Apher (2000) 0.86
Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clin Biochem (2011) 0.85
[Evaluation of the "N" factor in nonsmall cell lung cancer. Correlation between computerized tomography and pathologic anatomy]. Radiol Med (2000) 0.85
Familial pleural malignant mesothelioma: clustering in three sisters and one cousin. Cancer Lett (1998) 0.84
Critical presentation of pleuropulmonary blastoma. Pediatr Surg Int (2004) 0.84
Autoimmune myasthenia gravis after cardiac surgery. J Neurol Neurosurg Psychiatry (2003) 0.84
Familial autoimmune myasthenia gravis with different pathogenetic antibodies. J Neurol Neurosurg Psychiatry (1988) 0.84
Circulating CD4+CD25+ T regulatory and natural killer T cells in patients with myasthenia gravis: a flow cytometry study. J Biol Regul Homeost Agents (2005) 0.83
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases. J Neurol (1997) 0.83
Association of myasthenia gravis and antisynthetase syndrome: a case report. Int J Immunopathol Pharmacol (2004) 0.82
Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging? Eur J Cardiothorac Surg (2001) 0.82
Myasthenia gravis self-administered questionnaire: development of regional domains. Neurol Sci (2005) 0.81
TNF increases camptothecin-induced apoptosis by inhibition of NF-kappaB. Eur J Cancer (2003) 0.81
[Shall bowel obstruction caused by phytobezoar. Case report]. G Chir (2005) 0.81
From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors. Curr Med Chem (2013) 0.81
TP53 codon 72 polymorphism does not affect risk of cervical cancer in patients from The Gambia. Int J Biol Markers (2004) 0.80
Evaluation of Abbott CMV-M enzyme immunoassay for detection of cytomegalovirus immunoglobulin M antibody. J Clin Microbiol (1988) 0.80
Quality of life in patients with myasthenia gravis. Muscle Nerve (2002) 0.80
Ocular myasthenia: diagnostic value of single fibre EMG in the orbicularis oculi muscle. J Neurol Neurosurg Psychiatry (1993) 0.80